Skip to Content

Posts tagged with "Drug Assays"

  • Chemical Biology

    A Tour of the Outer Precincts

    You know, in an odd way, I’m actually more optimistic about drug discovery than I was a few years back. It’s due to the new tools that we have in molecular and cellular biology that we didn’t have before, and it’s also the number of unusual and interesting approaches that are being taken on the… Read More
  • Drug Assays

    Phenotypic Screening: The State of the Art

    I can recommend this article on phenotypic drug discovery from the latest Nature Reviews Drug Discovery. (For the nonspecialists in the crowd, there are two broad categories of screening for drug leads. One is “target-directed”, where you have an idea from other studies about what protein or pathway you want to affect, and you set… Read More
  • Drug Assays

    Model This?

    Via Ash Jogalekar on Twitter, I came across this new paper from researchers at AstraZeneca (and collaborators in Sweden, the UK, and Denmark) on the synthesis and activity of some plasmin inhibitors. Plasmin is an anticoagulation target, and has a lysine-binding site in its Kringle-1 domain (yeah, that’s the real name) that is the site of… Read More
  • Cancer

    MTH1: From Hot Topic to Devalidation?

    Here’s an argument that’s been going on inside the oncology drug development world over the last few years: is the enzyme MTH1 a great cancer target or a complete waste of time? MTH1, also known as NUDT1, degrades phosphates of 8-oxoguanine, an oxidized form of the regular guanine that cells know and love. That enzymatic… Read More
  • Drug Assays

    Cryptic Natural Products Appearing

    I last wrote about “cryptic natural products” here – this is the idea that there must be a great many interesting compounds produced by microorganisms that we have not seen yet. It’s for sure that there are many biosynthetic-looking gene clusters found in these species that don’t seem to be turned on most of the… Read More
  • Cancer

    How to Know When a New Target is Really a New Target

    This is an excellent article, and the title is self-recommending: “Common Pitfalls in Preclinical Cancer Target Validation”. The abstract speaketh the truth: An alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify dr… Read More
  • Biological News

    Thinking About Genetics and Disease

    Robert Plenge has an excellent post here, drawing on this recent paper from authors at Stanford. It’s on the idea of polygenic traits and disease, a very worthwhile subject considering what’s going on in the drug industry these days. I say that because I’ve been making the joke, for some time now, that if you were… Read More
  • Diabetes and Obesity

    A New Diabetes Approach? Small-Molecule Screening Wins Again

    The molecular biology/chemical biology tools we have now are quite something, and have opened up whole areas of research that previously wouldn’t have been feasible. But as a chemist, I’m glad to say that there’s often still nothing like a small molecule. That’s one of the things I take away from this recent paper in… Read More
  • Drug Assays

    Software Eats the World, But Biology Eats It

    I can strongly recommend this Bruce Booth post at LifeSciVC on computational models in drug discovery. He’s referencing Marc Andreessen’s famous “Why Software Is Eating the World” essay when he titles his “Four Decades of Hacking Biotech and Yet Biology Still Consumes Everything”. To tell you about where Bruce i… Read More
  • Biological News

    Silently Affecting the Immune System?

    Here’s a new paper in Nature Chemical Biology that might be lifting the lid on a poorly-understood set of side effects. A multi-institution team (centered in Vienna) has taken peripheral blood mononuclear cells (PBMCs, basically the leukocytes and monocytes) from a single patient and looked for immunomodulatory effects of known drugs. (The si… Read More